SCHEMBL15096320

SCHEMBL15096320

Cc1cc(Oc2ccc(C=O)c(Cl)c2)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
MCL1 Q07820 1/20 0.44
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 3/20 0.42
TRIM24 O15164 1/20 0.41
TYR P14679 1/20 0.41
TRIM33 Q9UPN9 1/20 0.41
HTR2A P28223 1/20 0.40
SLC6A4 P31645 1/20 0.40
KCNH2 Q12809 1/20 0.40
PKM P14618 1/20 0.39
HSP90AA1 P07900 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ERN1 O75460 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15096322 0.82 MEN1 (0.40) KMT2AMEN1MCL1KDM4EPOLB
SCHEMBL15096327 0.82 AR (0.44) KMT2AMEN1MCL1KDM4EPOLB
SCHEMBL6564428 0.82 KDM4E (0.56) KMT2AMEN1MCL1KDM4EPOLB
SCHEMBL9107585 0.81 KMT2A (0.47) KMT2AMEN1MCL1KDM4EPOLB
SCHEMBL8549679 0.81 TDP1 (0.52) TDP1KMT2AMEN1ALDH1A1TRIM24
SCHEMBL15809138 0.81 TDP1 (0.62) TDP1KMT2AMEN1ALDH1A1TRIM24
SCHEMBL3303519 0.81 ALDH1A1 (0.50) TDP1KMT2AMEN1ALDH1A1GAA
SCHEMBL7762056 0.79 LMNA (0.50) TDP1KMT2AALDH1A1SMN1; SMN2NPC1
SCHEMBL25333119 0.79 ALDH1A1 (0.53) TDP1KDM4EPOLBALDH1A1TRIM24
SCHEMBL25335529 0.78 TDP1 (0.42) TDP1KMT2AMEN1ALDH1A1TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 TDP1 1005/4885KMT2A 4340/4885MEN1 2428/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 TDP1 1005/4885KMT2A 4340/4885MEN1 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.